Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 25/100

PepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG

Key Takeaway: PepGen Inc. is facing a securities law lawsuit over allegations that it made false and misleading statements regarding its lead product candidate, PGN-EDO51. The lawsuit claims that the product's effectiveness and safety were overstated and that the CONNECT2 study had significant deficiencies, affecting its potential for FDA approval. As a result, it is suggested that the company may need to halt the study entirely. Shareholders who purchased shares during the specified class period are urged to register for possible participation in the class action case.

Market Sentiment Analysis

CONCERNS & RISKS

  • PepGen's lead product candidate, PGN-EDO51, is alleged to be less effective and safe than claimed.
  • The CONNECT2 study is purportedly deficient and poses risks for FDA approval.
  • There is a likelihood that PepGen may halt the CONNECT2 study due to these issues.
  • Public statements made by the company are claimed to be materially false and misleading.

Full Press Release Details

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).
Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 7, 2024 to March 3, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: August 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=156049&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for PepGen Inc. shareholders?

The class period for PepGen Inc. shareholders is March 7, 2024, to March 3, 2025.

What are the allegations against PepGen Inc.?

The allegations include misleading statements about PGN-EDO51's effectiveness and safety, and deficiencies in the phase two CONNECT2 study.

When is the deadline for shareholders to register?

Shareholders must register by August 8, 2025, to participate in the class action.

Do I need to be a lead plaintiff to participate?

No, you do not need to be appointed lead plaintiff to recover in this case.

What will shareholders receive after registration?

Registered shareholders will receive status updates via portfolio monitoring software.

Last updated: Jul 10, 2025